Alternative Data for Personalis
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 35 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 31 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,782 | Sign up | Sign up | Sign up |
| X Followers | 3,286 | Sign up | Sign up | Sign up |
| X Mentions | 25 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 339 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 44 | Sign up | Sign up | Sign up |
| Linkedin Employees | 383 | Sign up | Sign up | Sign up |
About Personalis
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific.
| Price | $6.59 |
| Target Price | Sign up |
| Volume | 1,394,754 |
| Market Cap | $869M |
| Year Range | $4.41 - $11.25 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Personalis to Participate in the TD Cowen 46th Annual Healthcare ConferenceFebruary 17 - Yahoo |
BTIG Maintains Buy on Personalis, Raises Price Target to $13February 11 - Benzinga |
|
 |
Personalis' MRD test receives Medicare coverage in lung cancer surveillanceFebruary 10 - Thefly.com |
Personalis shares are trading higher after the company announced Medicare coverage for the company's NeXT Personal molecular residual disease test for surveillance of patients with Stage I to III non-small cell lung cancer.February 9 - Benzinga |
|
 |
Personalis Gets Medicare Coverage For Lung Cancer Surveillance TestFebruary 9 - Benzinga |
Personalis Announced Medicare Coverage For Its NeXT Personal Molecular Residual Disease Test For Surveillance Of Patients With Stage I To III Non-Small Cell Lung CancerFebruary 9 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 14M | 13M | 1.9M | -22M | -19M | -0.240 |
| Q2 '25 | 17M | 12M | 4.8M | -20M | -17M | -0.230 |
| Q1 '25 | 21M | 13M | 7.2M | -16M | -13M | -0.180 |
| Q4 '24 | 17M | 12M | 4.6M | -16M | -14M | -0.230 |
| Q3 '24 | 26M | 17M | 8.7M | -39M | -36M | -0.640 |
Insider Transactions View All
| Tachibana Aaron filed to sell 164,458 shares at $11.5. January 23 '26 |
| Tempus AI, Inc. filed to buy 13,039,067 shares at $8.9. February 13 '26 |
| Tempus AI, Inc. filed to buy 13,011,067 shares at $8.4. February 13 '26 |
| Tempus AI, Inc. filed to buy 12,981,426 shares at $7.9. February 13 '26 |
| Tempus AI, Inc. filed to buy 12,949,996 shares at $7.9. February 13 '26 |
Similar companies
Read more about Personalis (PSNL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Personalis
The Market Cap of Personalis is $869M.
Currently, the price of one share of Personalis stock is $6.59.
The PSNL stock price chart above provides a comprehensive visual representation of Personalis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Personalis shares. Our platform offers an up-to-date PSNL stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Personalis (PSNL) does not offer dividends to its shareholders. Investors interested in Personalis should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Personalis are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
